Toxicologic Pathology Forum: ESTP/STP Working Group Opinion on the Evolving Landscape of New Approach Methodologies in Drug and Chemical Safety Development
- 28 August 2026
- journal article
- research article
- Published by SAGE Publications in Toxicologic Pathology
Abstract
In April 2025, the US Food and Drug Administration (FDA) introduced a bold roadmap to phase out animal testing in drug development by promoting the integration of New Approach Methodologies (NAMs), beginning with monoclonal antibodies (mAbs). Similar roadmaps have also been created by European health authorities and chemical safety agencies around the globe. This opinion paper from the European Society of Toxicologic Pathology and US Society of Toxicologic Pathology complex in vitro model and pathology working groups provides a balanced and expert perspective on the promise and limitations of these initiatives. NAMs, including in vitro, in silico, and refined in vivo models, offer exciting opportunities to improve human relevance, efficiency, and ethical standards in nonclinical safety assessment. While these approaches are already making meaningful contributions, current scientific and technical limitations prevent them from fully replacing animal studies in all contexts. At this time, NAMs should be viewed as powerful complementary tools whose appropriate integration depends on the context of use, validation, and continued collaboration across disciplines. Pathologists and investigative molecular pathology leaders are uniquely positioned to support this transition by bridging traditional methods with emerging technologies to enhance the safety and effectiveness of future therapeutics.Keywords
This publication has 55 references indexed in Scilit:
- New approach methodologies for assessing developmental toxicity of pharmaceuticals: Case examples and future directionsReproductive Toxicology, 2025
- Complement-ARIE: Catalyzing the development and adoption of new approach methodologiesNAM Journal, 2025
- Opportunities and insights from pharmaceutical companies on the current use of new approach methodologies in nonclinical safety assessmentDrug Discovery Today, 2025
- Do longer duration nonclinical toxicology studies provide predictive clinical safety value? The IQ consortium longer duration nonclinical to clinical translational databaseToxicology and Applied Pharmacology, 2024
- Establishment of a human cell-based in vitro battery to assess developmental neurotoxicity hazard of chemicalsChemosphere, 2022
- ALS mutations in both human skeletal muscle and motoneurons differentially affects neuromuscular junction integrity and functionBiomaterials, 2022
- Establishment of baseline profiles of 50 bile acids in preclinical toxicity species: A comprehensive assessment of translational differences and study design considerations for biomarker developmentToxicology and Applied Pharmacology, 2022
- Current nonclinical testing paradigm enables safe entry to First-In-Human clinical trials: The IQ consortium nonclinical to clinical translational databaseToxicology and Applied Pharmacology, 2017
- Addressing Positive Findings in Carcinogenicity Studies2015
- The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodiesCurrent Opinion in Biotechnology, 2009